425: TuHURA Biosciences Reports Fiscal Year 2024 Financial Results and Provides Corporate Update, Highlights Phase 3 Trial and Kineta Acquisition

TuHURA Biosciences announces its 2024 financial results, a corporate update focusing on its Phase 3 trial for IFx-2.0, and the planned acquisition of Kineta, Inc.

Summary

• TuHURA Biosciences reported its financial results for the year ended December 31, 2024, and provided a corporate update.
• A Phase 3 trial of IFx-2.0 as an adjunctive therapy with Keytruda for advanced Merkel cell carcinoma (MCC) is planned to initiate enrollment in Q2 2025.
• The MCC Phase 3 trial will be conducted under a Special Protocol Assessment (SPA) Agreement with the FDA.
• TuHURA is acquiring Kineta's Phase 2 ready, VISTA inhibiting antibody, with the transaction targeted for completion in Q2 2025.
• The company is expanding its discovery team for a first-in-class immune modulating Antibody Drug or Peptide Conjugate Program.
• TuHURA became a NASDAQ-listed Company and raised $36 million in 2024 to fund development programs and operations through late fourth quarter of 2025.
• Research and development (R&D) expense was $13.3 million for the year ended December 31, 2024, compared to $9.4 million in 2023.
• General and administrative (G&A) expenses were $4.3 million for the year ended December 31, 2024, compared to $4.1 million in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a strategic acquisition. However, the partial clinical hold and the need to satisfy closing conditions for the merger introduce some uncertainty.

Positives

• The SPA agreement with the FDA for the Phase 3 trial provides a clear regulatory pathway.
• The potential acquisition of Kineta's VISTA inhibitor adds a Phase 2 program in AML to TuHURA's development pipeline.
• The NASDAQ listing provides increased visibility and access to capital.
• The $36 million raised in 2024 provides funding for development programs and operations through late fourth quarter of 2025.
• The FDA recommended investigating IFx-2.0 in the first line setting rather than in patients progressing on first line therapy.

Negatives

• The Phase 3 trial is currently subject to a partial clinical hold relating to completion of certain CMC requirements.
• The Kineta acquisition is pending the satisfaction of funding conditions and other closing conditions, introducing uncertainty.
• The company incurred increased R&D expenses of $3.9 million in 2024, impacting profitability.

Risks

• The completion of the Kineta merger is subject to funding and other closing conditions.
• The Phase 3 trial is currently subject to a partial clinical hold.
• The company's success depends on the outcome of clinical trials and regulatory approvals.
• The biopharmaceutical sector is highly competitive.
• Macroeconomic conditions and geopolitical uncertainty in the global economy could impact the business.

Future Outlook

TuHURA plans to advance its late-stage clinical programs in 2025, complete enrollment in its Phase 3 trial next year, and continue developing novel Antibody Drug or Antibody Peptide Conjugates.

Management Comments

• James Bianco, President and CEO of TuHURA, stated that 2024 was a transformative year for the company.
• James Bianco commented that the company entered into a definitive agreement for a best-in-class VISTA inhibiting antibody, adding a Phase 2 program in AML to the development pipeline.

Industry Context

TuHURA is operating in the competitive immuno-oncology space, focusing on overcoming resistance to cancer immunotherapy, a significant challenge in the field. The acquisition of Kineta's VISTA inhibitor aligns with the industry trend of targeting immune checkpoints to enhance anti-cancer responses.

Comparison to Industry Standards

• TuHURA's focus on overcoming resistance to checkpoint inhibitors aligns with the strategies of companies like Bristol-Myers Squibb and Merck, which are also developing novel immunotherapies to address this issue.
• The development of Antibody Drug Conjugates (ADCs) is a growing trend in the industry, with companies like Seagen and Immunomedics leading the way.
• The SPA agreement with the FDA is a positive sign, as it indicates alignment with regulatory expectations, similar to companies like Amgen and Roche that have successfully utilized SPA agreements for their clinical trials.

Stakeholder Impact

• Shareholders may benefit from the potential success of the Phase 3 trial and the Kineta acquisition.
• Employees may experience changes due to the integration of Kineta's operations.
• Patients with advanced Merkel cell carcinoma may benefit from the development of IFx-2.0.
• The company's suppliers and partners may be affected by the company's strategic direction.

Next Steps

• Complete CMC requirements to lift the partial clinical hold on the Phase 3 trial.
• Initiate enrollment in the IFx-2.0 Phase 3 accelerated approval trial in Q2 2025.
• Close the acquisition of Kineta in Q2 2025.
• Initiate Phase 2 trial VISTA trial in NPM1 mutated AML in Q4 2025.
• Advance characterization toward lead compound selection for IFx-3.0 in Q4 2025.

Key Dates

Keywords

TuHURA Biosciences, Kineta, IFx-2.0, VISTA inhibitor, Phase 3 trial, Merger, Financial results, Immuno-oncology, FDA, MCC, AML